Figure 9. Supplementation with TG attenuated Hcy-induced Aβ pathology. (A) Levels of total amyloid precursor protein (APP), the β APP cleaving enzyme 1 (BACE1) cleaved APP [APPβ] and the total BACE1 were estimated by western blot (n = 6). (B-D) Quantification of the western blot results with APP and BACE1 normalized to β-actin and APPβ normalized to total APP. Total APP level remained unchanged, however the APPβ and BACE1 were high in the HHcy group while they were similar to control in the TG treatments groups. (E) ELISA assay for Aβ1-42 (n = 3) with significantly low levels of Aβ1-42 in the control, positive control and TG groups compared to level found in the HHcy group. The data were expressed as mean ± SEM. # P < 0.05, ## P < 0.01, ### P < 0.001 versus control; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 versus HHcy.